stockrow
Friday 6 November 2026
Export ESTA’s income statement to Excel — free account
Establishment Labs Holdings Inc.
ESTA Healthcare Medical Devices
Establishment Labs Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $211.1 million, up 27.1% from fiscal 2024.
- Revenue
- +31.7%
- EPS
- +31.6%
- Free cash flow
- +2.75%
- Total debt
- +18.3%
Quarter to June 2026, against a year earlier
66.77
2.35
+3.65%
Follow ESTA
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
10.52 | 7.41 | 10.23 | 6.36 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(155.69) | (394.52) | (13,325.34) | (107.93) | |
P/B ratio |
119.63 | 115.02 | 91.68 | 74.20 | |
Price to Tangible BV |
235.66 | 398.12 | 174.15 | 255.35 | |
EV/Sales |
11.38 | 8.29 | 11.14 | 7.39 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(86.52) | (55.18) | (46.22) | (19.75) | |
EV/FCF |
(67.30) | (45.15) | (40.82) | (18.02) | |
Quick Ratio |
2.27 | 1.75 | 1.86 | 1.97 | |
Current Ratio |
3.84 | 2.96 | 3.04 | 3.33 | |
Net Debt/EBITDA |
(117.48) | (47.26) | (148.23) | (118.57) | |
Debt/Assets |
74.36% | 70.82% | 69.30% | 72.72% | |
Debt/Equity |
12.11 | 16.82 | 10.51 | 15.06 | |
Asset Turnover |
0.72 | 0.67 | 0.60 | 0.61 | |
Operating CF/Net income |
1.41 | 0.32 | 0.06 | 1.01 | |
Capex/Depreciation |
(1.37) | (0.73) | (0.60) | (0.77) | |
Interest Coverage |
(0.61) | (0.92) | (0.54) | (0.65) | |
Research and Development Expense of Revenue |
7.54% | 8.75% | 8.41% | 8.47% | |
Selling, General and Administrative Expense of Revenue |
69.45% | 72.82% | 68.14% | 69.10% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
4.64% | 5.18% | 4.64% | 5.56% | |
Graham Net Nets |
(0.03) | (0.05) | (0.04) | (0.07) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.53%) | (2.62%) | (2.39%) | (6.93%) | |
Free Cash Flow Yield |
(1.61%) | (2.48%) | (2.67%) | (6.45%) | |
Revenue per Share |
2.24 | 2.00 | 2.18 | 1.82 | |
Operating CF per Share |
(0.55) | (0.14) | (0.01) | (0.38) | |
Capex per Share |
(0.12) | (0.07) | (0.06) | (0.07) | |
Free Cash Flow per Share |
(0.67) | (0.21) | (0.06) | (0.45) | |
Cash per Share |
2.36 | 2.27 | 2.55 | 2.38 | |
Shareholders Equity per Share |
0.72 | 0.49 | 0.80 | 0.55 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.72 | 0.49 | 0.80 | 0.55 | |
Free Cash Flow |
(20.25) | (6.27) | (1.82) | (13.21) | |
Working Capital |
183.17 | 162.67 | 167.80 | 167.62 | |
Capital Expenditures |
(3.65) | (1.96) | (1.66) | (1.96) | |
Net Current Asset Value |
(82.59) | (90.43) | (83.68) | (82.93) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.05 | 0.03 | 0.03 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
72.87 | 70.16 | 71.25 | 69.35 | |
Average Payables |
44.32 | 43.50 | 43.93 | 37.06 | |
Average Inventory |
89.83 | 88.54 | 82.19 | 77.64 | |
Average Assets |
340.80 | 342.20 | 352.00 | 310.79 | |
Average Common Equity |
22.19 | 26.67 | 38.32 | 24.54 |
Columns are period end dates